Ashley Misquitta, CFA CVS Health Corp CVS-N COMMENT Apr 17, 2018

Weak technical structure. 200-day MA falling, and stock price is below that. Longer-term weekly charts look just as tough. Earnings are tough in physical stores. Trump's (perhaps empty) threats to remove middle benefits management has impacted stock. Good yield at 5.81%, but how secure is it?

Keep a close eye on it, as technicals are telling you that things could get worse.

Company fundamentals are challenging. On paper, looks like a good model. But in practice, fail after fail. Overhang of healthcare malaise. Doesn't matter what the price is, you need fundamental quality to create value. Pass.

It has been a turn-around for a long time but hasn't performed well. It lost a few key contracts in the past two years. He prefers United Health.

Shocking that it rallied 25.8% in January, since it was spiralling last year, down 43%. There's no clear catalyst for their rally, though it helped that Medicare payments would increase from 2025 to 2026. He's waiting for their report next Wednesday before deciding.

He just bought it after earnings. Finally, we're seeing positive momentum with earnings growth and lower costs. It's an easy trade. An investor would now see a fundamental turnaround.

Is up 50.5% this year, benfitting from chief rival Walgreens are going private, and CVS' managed care business, Aetna, is putting up better numbers. CVS got too cheap last year, but mounted a comeback after hiring a new CEO. But it remains a drugstore chain, which he doesn't like, given Amazon's dominance.

Numbers are improving under the new CEO, with good numbers from Aetna and core drugstore business (they closed the weak performers). Though the health insurers like UNH have taken it on the chin recently, he expects Aetna to score. They report Thursday.

Was down 43% in 2024, led by their managed care business, to be one of the worst stocks of 2024. But that business is now finally turning around, +12% in revenues in Q2 YOY, and revenues beating the street. So, the health insurance side is doing much better. They raised revenue guidance and full-year earnings. Firing on nearly all cylinders: drug store, pharmacy benefits, health service division (including in-store medical clinics) saw 10.2% revenue growth. Also, the front-of-store and pharmacy delivered a strong revenue beat and growing 12.5% YOY as competitors have vanished (i.e. RiteAid). Pharmacy sales were +18% YOY. CVS shares are up 58% this year and trades at only 11x PE and pays a 3.7% dividend. The CEO has done a remarkable job this year. Has more room to run.

Turnaround story mainly due to activist actions, and that's not a great reason to buy. Its retail pharmacy space continues weak, and that's dragging down the pharmacy benefits side. Above 200-day MA, which is starting to move higher. Earnings growth still tepid at 6.5%.

CVS is a cheaper way to play the private benefits market, so he added that recently and it offers a better valuation than UNH.